A Phase 2 interventional study of Giredestrant and Anastrozole in Early Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 65 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.
Among the 16 studies testing giredestrant in Breast Neoplasms, this one is the 11th largest by enrollment, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 3rd registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Canada
Ages 18+
Genentech, Inc. · Sites in United States
Ages 18+ · Women only
Hoffmann-La Roche · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18+ · Women only
Fondazione Oncotech · Sites in Italy
Ages 18+ · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, giredestrant is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 302 across the 16 interventional studies. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 5 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 65th largest by enrollment of the 170 interventional ones that give a count, is one of 7 that started in 2020, is one of 65 in phase 2, and was the 199th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
2 of the studies testing giredestrant in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03332797Genentech, Inc.A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | 2027-07-31 |
| NCT07054190Hoffmann-La RocheA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing giredestrant in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a randomized, multicenter, open-label, two-arm, Phase II study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant versus anastrozole (in the window-of-opportunity phase) and giredestrant plus palbociclib compared with anastrozole plus palbociclib (in the neoadjuvant phase) in postmenopausal women with untreated, estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, early breast cancer.
The study consists of a screening period of up to 28 days, a window-of-opportunity phase for 14 days, followed by a neoadjuvant treatment phase for 16 weeks (four 28-day cycles), surgery, and an end of study visit (28 days after the final dose of study treatment).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Giredestrant · Drug: Palbociclib · Procedure: Surgery
Drug: Anastrozole · Drug: Palbociclib · Procedure: Surgery
During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
Also known as: GDC-9545, RO7197597, RG6171
During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.
During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.
Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
Relative Percent Change in Ki67 Scores From Baseline to Week 2
Ki67 is a proliferation biomarker with prognostic value in ER-positive breast cancer. Ki67 scores were centrally assessed with immunohistochemistry and defined as a percentage of positively stained tumor cell nuclei among the total number of tumor cells assessed, with a potential range of 0-100%. A score of 0% indicates no tumor cell nuclei with Ki67 staining and a score of 100% indicates all tumor cell nuclei are positively stained with Ki67. The relative percentage change was calculated using Ki67 scores at Baseline and Week 2. Relative Percent Change was defined as Week 2 Ki67 percentage score/Baseline Ki67 percentage score\*100. A smaller value of relative percentage change indicates improvement.
Time frame: Baseline, Week 2
Overall Response Rate (ORR) by Ultrasound as Determined by the Investigator
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR), as determined by the investigator according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Ultrasound and clinical exam were used to assess response. CR per mRECIST was defined as the disappearance of all target lesions. PR per mRECIST was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. An estimate of ORR and its 95% confidence interval (CI) was calculated using the Clopper-Pearson method.
Time frame: Baseline up to Cycle 4 Day 1 (each cycle is 28 days)
Complete Cell Cycle Arrest (CCCA) Rate at Week 2
CCCA was defined as the percentage of participants with centrally assessed Ki67 scores ≤2.7%. The CCCA rate at Week 2 was summarized.
Time frame: Week 2
Number of Participants With Adverse Events (AEs) With Severity Determined in Accordance With National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)
AE is any untoward medical occurrence in clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable \& unintended sign, symptom/disease temporally associated with use of a medicinal product, whether or not related to medicinal product. Preexisting conditions which worsen during a study also considered as AEs. Severity of AEs was determined per NCI CTCAE v5.0. Grade 1: Mild; asymptomatic/mild symptoms; clinical/diagnostic observations only; or intervention not indicated; Grade 2: Moderate; minimal, local/non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3: Severe/medically significant, but not immediately life-threatening: hospitalization/prolongation of hospitalization indicated; disabling/limiting self-care activities of daily living; Grade 4: Life-threatening consequences/urgent intervention indicated; Grade 5: Death related to AE.
Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Change From Baseline in Respiratory Rate Over Time
Respiratory rate was measured while the participant was in a seated position.
Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Change From Baseline in Pulse Rate Over Time
Pulse rate was measured while the participant was in a seated position.
Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Change From Baseline in Systolic Blood Pressure Over Time
Systolic blood pressure was measured while the participant was in a seated position.
Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Change From Baseline in Diastolic Blood Pressure Over Time
Diastolic blood pressure was measured while the participant was in a seated position.
Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Change From Baseline in Body Temperature Over Time
Time frame: Baseline; Cycles 1-2: Day 1 and Day 15; Cycles 3-4: Day 1; day of surgery (up to 2 weeks after the final dose of study treatment [approximately Week 18]) and end of study (up to approximately 24 weeks)
Number of Participants With Shifts in Hematology Test Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline
Hematology test parameters were measured per NCI CTCAE v5.0. Grade 0 is normal, and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Number of participants with shift in the hematology values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. A marked reference range for hemoglobin 12.3-15.3 grams per deciliter (g/dL), lymphocytes absolute (Abs) 1.0-4.8 10\^3/microliters (uL), neutrophils total, Abs, 1.8-8.5 10\^3/uL, platelet 100-450 10\^9/liter (L), total leukocyte 4.4-11 10\^9/L.
Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Number of Participants With Shifts in Blood Chemistry Parameters From NCI-CTCAE Grade 0-2 at Baseline to Grade 3-4 at Post-baseline
Blood chemistry parameters were measured per NCI CTCAE v5.0. Grade 0=normal, and Grades 1 to 4 represent worsening levels of parameter outside of normal range in the specified direction of abnormality (high \& low are above \& below the range, respectively). Number of participants with shift in blood chemistry values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. Marked reference range for albumin 32-45 grams per liter (g/L), alkaline phosphatase 20-130 units per liter (U/L), serum glutamic pyruvic transaminase (SGPT)/ alanine transaminase (ALT) 4-36 U/L, serum glutamic oxaloacetic transaminase (SGOT)/ aspartate transaminase (AST) 8-33 U/L, calcium 2.3-2.74 millimoles per liter (mmol/L), cholesterol 3.88-6.47mmol/L, creatinine 6-12 milligrams per liter (mg/L), glucose 3.9-6.1 mmol/L, potassium 3.5-5.0 mmol/L, sodium 135-147 mmol/L, bilirubin 2-21 micromoles per liter (μmol/L), triglycerides 0.11-2.15 mmol/L, \& uric acid 2.7-7.3 milligrams per deciliter (mg/dL).
Time frame: From baseline up to 28 days after the last dose (up to approximately 24 weeks)
Plasma Concentration of Giredestrant at Specified Timepoints
Time frame: Window of Opportunity Phase: Day 1 (3 hours Postdose) and Day 15 (Predose) during Cycle 0 (the 15-day period in Window of Opportunity Phase is called Cycle 0 for PK analysis); Neoadjuvant Phase: Cycle 2 Day 1, Predose
Participants took part in this study at 64 investigative sites in Australia, Brazil, Germany, Hungary, Korea, Poland, Russia, Spain, Taiwan, the United States, and Ukraine, from 4 September 2020 to 24 November 2021.
| Milestone | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Started | 112 | 109 |
| Completed | 108 | 98 |
| Not completed | 4 | 11 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Progressive disease | 0 | 4 |
| Withdrew: Protocol deviation | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
Ki67 is a proliferation biomarker with prognostic value in ER-positive breast cancer. Ki67 scores were centrally assessed with immunohistochemistry and defined as a percentage of positively stained tumor cell nuclei among the total number of tumor cells assessed, with a potential range of 0-100%. A score of 0% indicates no tumor cell nuclei with Ki67 staining and a score of 100% indicates all tumor cell nuclei are positively stained with Ki67. The relative percentage change was calculated using Ki67 scores at Baseline and Week 2. Relative Percent Change was defined as Week 2 Ki67 percentage score/Baseline Ki67 percentage score\*100. A smaller value of relative percentage change indicates improvement.
| percent change | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Relative Percent Change in Ki67 Scores From Baseline to Week 2 | 25 (20 to 30) | 33 (27 to 41) |
ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR), as determined by the investigator according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Ultrasound and clinical exam were used to assess response. CR per mRECIST was defined as the disappearance of all target lesions. PR per mRECIST was defined as at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. An estimate of ORR and its 95% confidence interval (CI) was calculated using the Clopper-Pearson method.
| percentage of participants | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Overall Response Rate (ORR) by Ultrasound as Determined by the Investigator | 50.0 (40.40 to 59.60) | 49.1 (39.33 to 58.87) |
CCCA was defined as the percentage of participants with centrally assessed Ki67 scores ≤2.7%. The CCCA rate at Week 2 was summarized.
| percentage of participants | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Complete Cell Cycle Arrest (CCCA) Rate at Week 2 | 19.6 | 12.8 |
AE is any untoward medical occurrence in clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable \& unintended sign, symptom/disease temporally associated with use of a medicinal product, whether or not related to medicinal product. Preexisting conditions which worsen during a study also considered as AEs. Severity of AEs was determined per NCI CTCAE v5.0. Grade 1: Mild; asymptomatic/mild symptoms; clinical/diagnostic observations only; or intervention not indicated; Grade 2: Moderate; minimal, local/non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living; Grade 3: Severe/medically significant, but not immediately life-threatening: hospitalization/prolongation of hospitalization indicated; disabling/limiting self-care activities of daily living; Grade 4: Life-threatening consequences/urgent intervention indicated; Grade 5: Death related to AE.
| Participants | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| AEs | 104 | 98 |
| Grade 1 | 19 | 20 |
| Grade 2 | 35 | 31 |
| Grade 3 | 45 | 45 |
| Grade 4 | 4 | 2 |
| Grade 5 | 1 | 0 |
Respiratory rate was measured while the participant was in a seated position.
| breath/minute (min) | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Baseline | 17.16 ± 2.27 | 17.10 ± 2.05 |
| Change from Baseline at Cycle 1 Day 1 | 0.30 ± 2.12 | 0.26 ± 1.50 |
| Change from Baseline at Cycle 1 Day 15 | -0.01 ± 1.49 | -0.06 ± 1.36 |
| Change from Baseline at Cycle 2 Day 1 | -0.10 ± 1.83 | 0.16 ± 1.34 |
| Change from Baseline at Cycle 2 Day 15 | -0.24 ± 1.71 | -0.03 ± 1.64 |
| Change from Baseline at Cycle 3 Day 1 | 0.07 ± 1.58 | 0.01 ± 1.61 |
| Change from Baseline at Cycle 4 Day 1 | -0.04 ± 1.71 | 0.01 ± 1.53 |
| Change from Baseline at Day of Surgery | 0.04 ± 1.72 | -0.02 ± 1.69 |
| Change from Baseline at End of Study | -0.26 ± 1.65 | 0.01 ± 1.42 |
Pulse rate was measured while the participant was in a seated position.
| beats/min | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Baseline | 75.86 ± 10.67 | 76.73 ± 9.85 |
| Change from Baseline at Cycle 1 Day 1 | -4.74 ± 9.07 | -1.96 ± 9.43 |
| Change from Baseline at Cycle 1 Day 15 | -6.02 ± 12.02 | -1.47 ± 8.15 |
| Change from Baseline at Cycle 2 Day 1 | -5.20 ± 10.26 | -1.11 ± 10.79 |
| Change from Baseline at Cycle 2 Day 15 | -7.68 ± 11.03 | -1.95 ± 8.64 |
| Change from Baseline at Cycle 3 Day 1 | -5.47 ± 11.61 | -0.81 ± 10.83 |
| Change from Baseline at Cycle 4 Day 1 | -5.67 ± 9.79 | -1.11 ± 10.62 |
| Change from Baseline at Day of Surgery | -4.14 ± 11.25 | -1.26 ± 10.46 |
| Change from Baseline at End of Study | -0.61 ± 10.74 | 1.59 ± 10.44 |
Systolic blood pressure was measured while the participant was in a seated position.
| millimeters of mercury (mmHg) | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Baseline | 135.63 ± 14.13 | 130.03 ± 16.43 |
| Change from Baseline at Cycle 1 Day 1 | -0.82 ± 11.11 | 1.12 ± 13.65 |
| Change from Baseline at Cycle 1 Day 15 | -2.55 ± 14.01 | 0.23 ± 15.85 |
| Change from Baseline at Cycle 2 Day 1 | -2.08 ± 14.13 | 0.28 ± 14.43 |
| Change from Baseline at Cycle 2 Day 15 | -4.25 ± 15.37 | 0.16 ± 16.49 |
| Change from Baseline at Cycle 3 Day 1 | -2.66 ± 16.95 | 0.33 ± 15.81 |
| Change from Baseline at Cycle 4 Day 1 | -1.29 ± 15.30 | -0.25 ± 14.17 |
| Change from Baseline at Day of Surgery | -2.35 ± 13.79 | 1.51 ± 15.24 |
| Change from Baseline at End of Study | -5.38 ± 13.98 | -1.67 ± 16.20 |
Diastolic blood pressure was measured while the participant was in a seated position.
| mmHg | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Baseline | 80.40 ± 8.84 | 78.49 ± 9.55 |
| Change from Baseline at Cycle 1 Day 1 | -2.42 ± 7.77 | 0.39 ± 8.13 |
| Change from Baseline at Cycle 1 Day 15 | -4.80 ± 8.58 | -2.42 ± 8.71 |
| Change from Baseline at Cycle 2 Day 1 | -4.79 ± 10.08 | -0.76 ± 8.80 |
| Change from Baseline at Cycle 2 Day 15 | -5.64 ± 9.24 | -1.32 ± 9.64 |
| Change from Baseline at Cycle 3 Day 1 | -5.25 ± 8.51 | -0.16 ± 9.52 |
| Change from Baseline at Cycle 4 Day 1 | -4.35 ± 9.31 | -2.57 ± 9.50 |
| Change from Baseline at Day of Surgery | -4.93 ± 8.72 | -2.15 ± 9.58 |
| Change from Baseline at End of Study | -2.73 ± 8.37 | -2.52 ± 12.11 |
| Celsius (C) | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Baseline | 36.35 ± 0.41 | 36.45 ± 0.38 |
| Change from Baseline at Cycle 1 Day 1 | 0.07 ± 0.39 | 0.04 ± 0.36 |
| Change from Baseline at Cycle 1 Day 15 | 0.01 ± 0.41 | -0.01 ± 0.43 |
| Change from Baseline at Cycle 2 Day 1 | 0.03 ± 0.40 | -0.04 ± 0.52 |
| Change from Baseline at Cycle 2 Day 15 | -0.03 ± 0.37 | -0.12 ± 0.47 |
| Change from Baseline at Cycle 3 Day 1 | -0.04 ± 0.42 | 0.01 ± 0.39 |
| Change from Baseline at Cycle 4 Day 1 | -0.03 ± 0.37 | -0.08 ± 0.38 |
| Change from Baseline at Day of Surgery | 0.06 ± 0.39 | -0.01 ± 0.38 |
| Change from Baseline at End of Study | 0.05 ± 0.39 | -0.04 ± 0.48 |
Hematology test parameters were measured per NCI CTCAE v5.0. Grade 0 is normal, and Grades 1 to 4 represent worsening levels of the parameter outside of the normal range in the specified direction of the abnormality (high and low are above and below the range, respectively). Number of participants with shift in the hematology values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. A marked reference range for hemoglobin 12.3-15.3 grams per deciliter (g/dL), lymphocytes absolute (Abs) 1.0-4.8 10\^3/microliters (uL), neutrophils total, Abs, 1.8-8.5 10\^3/uL, platelet 100-450 10\^9/liter (L), total leukocyte 4.4-11 10\^9/L.
| Participants | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Hemoglobin: Low | 3 | 1 |
| Hemoglobin: High | 0 | 1 |
| Lymphocytes Abs: Low | 9 | 2 |
| Lymphocytes Abs: High | 1 | 2 |
| Neutrophils, Total, Abs: Low | 43 | 38 |
| Platelet: Low | 0 | 0 |
| Total Leukocyte Count: Low | 15 | 11 |
| Total Leukocyte Count: High | 0 | 0 |
Blood chemistry parameters were measured per NCI CTCAE v5.0. Grade 0=normal, and Grades 1 to 4 represent worsening levels of parameter outside of normal range in the specified direction of abnormality (high \& low are above \& below the range, respectively). Number of participants with shift in blood chemistry values from grade 0-2 at baseline to grade 3-4 at post-baseline were reported. Marked reference range for albumin 32-45 grams per liter (g/L), alkaline phosphatase 20-130 units per liter (U/L), serum glutamic pyruvic transaminase (SGPT)/ alanine transaminase (ALT) 4-36 U/L, serum glutamic oxaloacetic transaminase (SGOT)/ aspartate transaminase (AST) 8-33 U/L, calcium 2.3-2.74 millimoles per liter (mmol/L), cholesterol 3.88-6.47mmol/L, creatinine 6-12 milligrams per liter (mg/L), glucose 3.9-6.1 mmol/L, potassium 3.5-5.0 mmol/L, sodium 135-147 mmol/L, bilirubin 2-21 micromoles per liter (μmol/L), triglycerides 0.11-2.15 mmol/L, \& uric acid 2.7-7.3 milligrams per deciliter (mg/dL).
| Participants | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Albumin: low | 1 | 0 |
| Alkaline Phosphatase: High | 0 | 0 |
| SGPT/ALT: High | 1 | 5 |
| SGOT/AST: High | 1 | 3 |
| Calcium: Low | 0 | 3 |
| Calcium: High | 0 | 0 |
| Cholesterol: High | 0 | 0 |
| Creatinine: High | 0 | 1 |
| Glucose: Low | 0 | 0 |
| Potassium: Low | 0 | 0 |
| Potassium: High | 0 | 0 |
| Sodium: Low | 0 | 0 |
| Sodium: High | 0 | 0 |
| Bilirubin: High | 0 | 0 |
| Triglycerides: High | 1 | 0 |
| Uric Acid: High | 21 | 22 |
| nanograms per milliliters (ng/mL) | Giredestrant + Palbociclib |
|---|---|
| Window of Opportunity Phase: Cycle 0 Day 1, 3-h Postdose | 81.8 ± 284 |
| Window of Opportunity Phase: Cycle 0 Day 15, Predose | 137 ± 61.1 |
| Neoadjuvant Phase: Cycle 2 Day 1, Predose | 130 ± 122 |
Collected over From baseline up to 28 days after the last dose (up to approximately 24 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Giredestrant + Palbociclib | 1/112 (0.9%) | 5/112 (4.5%) | 99/112 (88.4%) |
| Anastrozole + Palbociclib | 0/109 (0%) | 2/109 (1.8%) | 93/109 (85.3%) |
| Event | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 0/112 | 1/109 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/112 | 1/109 |
| Myocardial infarctionCardiac disorders | 1/112 | 0/109 |
| PyrexiaGeneral disorders | 1/112 | 0/109 |
| COVID-19Infections and infestations | 1/112 | 0/109 |
| Hip fractureInjury, poisoning and procedural complications | 1/112 | 0/109 |
| Uterine perforationInjury, poisoning and procedural complications | 1/112 | 0/109 |
| Event | Giredestrant + Palbociclib | Anastrozole + Palbociclib |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 46/112 | 44/109 |
| AstheniaGeneral disorders | 25/112 | 27/109 |
| Neutrophil count decreasedInvestigations | 26/112 | 24/109 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/112 | 21/109 |
| DiarrhoeaGastrointestinal disorders | 8/112 | 18/109 |
| FatigueGeneral disorders | 10/112 | 18/109 |
| LeukopeniaBlood and lymphatic system disorders | 14/112 | 16/109 |
| Hot flushVascular disorders | 16/112 | 16/109 |
| NauseaGastrointestinal disorders | 16/112 | 13/109 |
| White blood cell count decreasedInvestigations | 14/112 | 10/109 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Giredestrant + Palbociclib | Anastrozole + Palbociclib | Total |
|---|---|---|---|
| Mean | 63.1 ± 7.9 | 62.4 ± 9.3 | 62.8 ± 8.6 |
| Sex: Female, Male(Participants) | Giredestrant + Palbociclib | Anastrozole + Palbociclib | Total |
|---|---|---|---|
| Female | 112 | 109 | 221 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Giredestrant + Palbociclib | Anastrozole + Palbociclib | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 11 | 27 |
| Not Hispanic or Latino | 95 | 98 | 193 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Giredestrant + Palbociclib | Anastrozole + Palbociclib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 9 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 100 | 94 | 194 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 5 | 9 |
| Ki67 Scores(percent Ki67 score) | Giredestrant + Palbociclib | Anastrozole + Palbociclib | Total |
|---|---|---|---|
| Mean | 37.92 (6.6 to 96.3) | 41.66 (7.8 to 98.9) | 39.76 (6.6 to 98.9) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Sep 2020 to primary completion in Jul 2021, 10 months.
Results were first posted in Feb 2023, 1 year 6 months after primary completion. A results delay was requested in Jun 2022.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 10 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Giredestrant